Alexion Pharma Updates 2020 Financial Guidance - Quick Facts

(RTTNews) - Alexion Pharmaceuticals, Inc. (ALXN) said, for fiscal 2020, the company now projects non GAAP earnings per share in a range of $10.45 to $10.75, revised from prior guidance range of $10.65 to $10.85. Total revenues are anticipated in the range of $5.23 billion to $5.33 billion, updated from prior guidance range of $5.50 billion to $5.56 billion. The company noted that the updated guidance excludes the impact of the recently announced agreement to acquire Portola.

First quarter non-GAAP earnings per share was $3.22, a 35 percent increase from prior year. Total revenues were $1.45 billion, a 27 percent increase from prior year.